The DOI matches its Crossref record.
Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pegylated liposomal doxorubicin (Doxil/Caelyx), for instance, showed similar efficacy endpoints with significantly reduced cardiotoxicity versus conventional doxorubicin in metastatic breast cancer, illustrating that the most consistent clinical value may be toxicity mitigation and exposure smoothing rather than reliably deeper parenchymal penetration[123].”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [123]
In the citing paper
“illustrating that the most consistent clinical value may be toxicity mitigation and exposure smoothing rather than reliably deeper parenchymal penetration[123].”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- de Baat, 2022, Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines, Cochrane Database Syst Rev, 9, CD014638
- Marty, 2006, Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy, Ann Oncol, 17, 614, 10.1093/annonc/mdj134 · DOI
- O’Brien, 2004, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann Oncol, 15, 440, 10.1093/annonc/mdh097 · DOI
- Jones, 2021, Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial, Clin Cancer Res, 27, 3861, 10.1158/1078-0432.CCR-20-4592 · DOI
- Salz, 2017, Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors, J Clin Oncol, 35, 3837, 10.1200/JCO.2017.72.4211 · DOI
- Armenian, 2017, Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary, J Oncol Pract, 13, 270, 10.1200/JOP.2016.018770 · DOI
- Lyon, 2022, 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), Eur Heart J, 23, e333
- Ganatra, 2019, Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series, Cardiooncology, 5, 1
- Upshaw, 2023, Association of preexisting heart failure with outcomes in older patients with diffuse large B-cell lymphoma, JAMA Cardiol, 8, 453, 10.1001/jamacardio.2023.0303 · DOI
Cited by
Sorted by citations
Sheng, J., Yuan, W., Zhang, M., Chen, Z., Qi, Y., Zhao, Y., & Zhang, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04028-7 · Cited by 35
Metadata
- Authors
- Upshaw, J. N., Parson, S. K., Buchsbaum, R. J., Schlam, I., Ruddy, K. J., Durani, U., Epperla, N., & Leong, D. P.
- Venue
- JACC: CardioOncology
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 6
- Issue
- 2
- Pages
- 322-324
- ISSN
- 2666-0873
- PMC
- PMC11103024
- Cited by
- 49
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines. https://app.cochat.ai/papers/10.1016/j.jaccao.2024.02.004
- The paper
- Upshaw, J. N., Parson, S. K., Buchsbaum, R. J., Schlam, I., Ruddy, K. J., Durani, U., Epperla, N., & Leong, D. P. (2024). Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines. JACC: CardioOncology. https://doi.org/10.1016/j.jaccao.2024.02.004
